BioArctic Sweden

BioArctic's partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer's disease in the EU

View original content:https://www.prnewswire.co.uk/news-releases/bioarctics-partner-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-the-eu-301718616.html